Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
5-Amino-1MQ
Also known as: 5-Amino-1-methylquinolinium, 5A1MQ
5-Amino-1MQ is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor, technically not a peptide but commonly categorized with underground peptides in performance enhancement contexts. NNMT is an enzyme linked to obesity and metabolic dysfunction. Preclinical studies in diet-induced obesity models showed significant fat loss and metabolic improvement. No human clinical trials have been published.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 42816-54-2 |
| Molecular Formula | C10H11N2O |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and depletes SAM (S-adenosylmethionine). By blocking NNMT, it increases intracellular NAD+ and SAM levels, enhancing cellular energy metabolism. In animal models, this activates sirtuin pathways, increases fat oxidation, and promotes energy expenditure in white adipose tissue.
Dosing Research
No established human dosing. Underground protocols commonly use 50-150 mg orally, 1-2 times daily. Being a small molecule, it has reasonable oral bioavailability unlike most peptides. Cycles of 4-8 weeks are typical. Some protocols suggest taking with meals.
Side Effects & Risks
No human safety data. As an NNMT inhibitor, it affects methyl donor metabolism, which could have wide-ranging epigenetic consequences. Theoretical risks include disruption of one-carbon metabolism, effects on neurotransmitter methylation, and liver toxicity. Gastrointestinal discomfort is anecdotally reported.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.